Predicting Cardiovascular Risk in Participants Treated With Tirzepatide in the SURPASS 1-5 Trials

被引：0
|
作者：
Wiese, Russell J.
Wang, Hui
Mody, Reema
Benneyworth, Brian D.
机构：
来源：
CIRCULATION | 2023年 / 148卷
关键词：
Diabetes (Type II); Cardiovascular Risk; Drugs; Prediction model; Clinical trials;
D O I：
10.1161/circ.148.suppl_1.16589
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A16589
引用
收藏
页数：2
相关论文
共 50 条
  • [41] COMPARED TO INSULIN GLARGINE, TIRZEPATIDE REDUCES THE PREVALENCE OF THE METABOLIC SYNDROME IN PATIENTS WITH TYPE 2 DIABETES AND HIGH CARDIOVASCULAR RISK: POST-HOC ANALYSIS OF SURPASS-4
    Nicholls, Stephen J.
    D'Alessio, David
    Wiese, Russell
    Pavo, Imre
    Zeytinoglu, Meltem
    Romera, Irene
    Weerakkody, Govinda J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 1628 - 1628
  • [42] Semaglutide provides superior glycaemic control across SUSTAIN 1-5 clinical trials
    Petrie, J.
    Chow, F.
    Fonseca, V.
    Mehta, R.
    Thomsen, H. F.
    Thielke, D.
    Ahmann, A.
    DIABETIC MEDICINE, 2018, 35 : 83 - 83
  • [43] Semaglutide Provides Superior Glycemic Control across SUSTAIN 1-5 Clinical Trials
    Imamine, Rui
    Satou, Ai
    Mase, Hajime
    Mizoguchi, Asako
    Minatoguchi, Makiko
    Kusama, Minoru
    Watarai, Atuko
    Kawamura, Takahiko
    Hotta, Nigishi
    Nakashima, Eitaro
    DIABETES, 2017, 66 : A285 - A285
  • [44] Achievement of HbA1c ≤6.5% (47.5 mmol/mol), with ≥10% weight loss, without hypoglycaemia in patients treated with tirzepatide vs comparators in SURPASS program
    Levine, J. A.
    Cheng, A.
    Choudhary, P.
    Lingvay, I.
    Valderas, E. Gomez
    Allen, S. E.
    Ranta, K.
    Thieu, V. T.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S300 - S300
  • [45] Tirzepatide Reduces High-Sensitivity C-reactive Protein in Patients With Type 2 Diabetes and High Cardiovascular Risk: A Post Hoc Analysis of the SURPASS-4 Trial
    Bhatt, Deepak L.
    Wilson, Jonathan M.
    Wiese, Russell J.
    Yang, Zhengyu
    Duffin, Kevin L.
    Pavo, Imre
    CIRCULATION, 2023, 148
  • [46] Sustainability of HbA1c control of tirzepatide vs insulin glargine in people with T2D and CV risk (SURPASS-4)
    Kahn, S.
    Del Prato, S.
    Pavo, I.
    Franco, D. R.
    Yang, Z.
    Hemmingway, A.
    Wiese, R. J.
    Pearson, E. R.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 197
  • [47] Semaglutide Provides Superior Body Weight Reduction across SUSTAIN 1-5 Clinical Trials
    Lingvay, Ildiko
    Luedemann, Joerg
    Marre, Michel
    Uusinarkaus, Kari
    Woo, Vincent
    Thomsen, Henrik F.
    Wijayasinghe, Nelun
    Davies, Melanie
    DIABETES, 2017, 66 : A64 - A64
  • [48] Semaglutide provides superior body weight reduction across SUSTAIN 1-5 clinical trials
    Davies, M. J.
    Luedemann, J.
    Marre, M.
    Uusinarkaus, K.
    Woo, V.
    Thomsen, H. F.
    Wijayasinghe, N.
    Lingvay, I.
    DIABETIC MEDICINE, 2018, 35 : 82 - 82
  • [49] Responder analysis of subjects achieving HbA1c≥1% and weight loss ≥5% across SUSTAIN 1-5 clinical trials
    Rodbard, H. W.
    Bellary, S.
    Hramiak, I.
    Seino, Y.
    Silver, R.
    Bergan, E. Q.
    Birch, S.
    Aroda, V. R.
    DIABETOLOGIA, 2017, 60 : S379 - S379
  • [50] Responder analysis of subjects achieving HbA1c ≥1% and weight loss ≥5% across SUSTAIN 1-5 clinical trials
    Bellary, S.
    Rodbard, H.
    Hramiak, I.
    Seino, Y.
    Silver, R.
    Bergan, E. Q.
    Birch, S.
    Aroda, V.
    DIABETIC MEDICINE, 2018, 35 : 34 - 34
12345